SCHEMBL20256150

SCHEMBL20256150

O=C1c2ccccc2-c2nc(Cl)nc3cccc1c23

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 5/20 0.50
MEN1 O00255 3/20 0.50
KMT2A Q03164 3/20 0.50
APEX1 P27695 2/20 0.50
PABPC1 P11940 3/20 0.49
MAOA P21397 1/20 0.49
NPC1 O15118 4/20 0.49
RAB9A P51151 4/20 0.49
ALDH1A1 P00352 2/20 0.49
SMN1; SMN2 Q16637 2/20 0.49
AHR P35869 1/20 0.49
CYP3A4 P08684 2/20 0.46
CASP1 P29466 2/20 0.46
CASP7 P55210 2/20 0.46
DNMT1 P26358 2/20 0.46
EIF2AK2 P19525 2/20 0.45
MAPK12 P53778 2/20 0.45
MAPK1 P28482 2/20 0.45
KDM4E B2RXH2 1/20 0.45
CDC7 O00311 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17413769 0.86 ALDH1A1 (0.41) MAPTMEN1KMT2AAPEX1PABPC1
SCHEMBL7534095 0.80 MAPT (0.58) MAPTMEN1KMT2AAPEX1PABPC1
SCHEMBL7535432 0.78 MAPT (0.48) MAPTMEN1KMT2AAPEX1PABPC1
SCHEMBL10985872 0.77 ELANE (0.51) KMT2ANPC1RAB9AALDH1A1KDM4E
SCHEMBL19162426 0.76 MAPT (0.50) MAPTMEN1KMT2AAPEX1PABPC1
SCHEMBL20256152 0.73 GPR3 (0.44) MAPTKMT2APABPC1ALDH1A1SMN1; SMN2
SCHEMBL460367 0.72 MAOA (0.56) MAPTMEN1KMT2AAPEX1PABPC1
SCHEMBL19044531 0.72 NPY5R (0.41) MAPTPABPC1ALDH1A1SMN1; SMN2KDM4E
SCHEMBL19044522 0.72 KDM4E (0.47) MAPTNPC1RAB9AALDH1A1SMN1; SMN2
SCHEMBL25470096 0.70 ALDH1A1 (0.43) MAPTMEN1KMT2AMAOANPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3978491-A1 NITROGEN-CONTAINING HETEROCYCLES FOR USE IN OLEDS Merck Patent GmbH (DE) 2022-04-06 EP disclosed
EP-3548477-B1 NITROGEN-CONTAINING HETEROCYCLES FOR USE IN OLEDS MERCK PATENT GMBH (DE) 2021-10-27 EP disclosed
US-20200066994-A1 NITROGEN-CONTAINING HETEROCYCLES FOR USE IN OLEDS MERCK PATENT GMBH (DE) 2020-02-27 US disclosed
WO-2018104195-A1 NITROGEN-CONTAINING HETEROCYCLES FOR USE IN OLEDS MERCK PATENT GMBH (DE) 2018-06-14 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20200066994-A1 NITROGEN-CONTAINING HETEROCYCLES FOR USE IN OLEDS CYCS, OCIAD2, OCIAD1 MAPT 2949/4885MEN1 3952/4885KMT2A 3124/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.